Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $137
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $120 to $137.
September 13, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Neurocrine Biosciences and raises the price target from $120 to $137.
The news is directly related to Neurocrine Biosciences. The Outperform rating maintained by Wedbush and the increase in price target from $120 to $137 indicates a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100